These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

274 related items for PubMed ID: 22573520

  • 1. Use of eltrombopag, a thrombopoietin receptor agonist, in post-transplantation thrombocytopenia.
    Reid R, Bennett JM, Becker M, Chen Y, Milner L, Phillips GL, Liesveld J.
    Am J Hematol; 2012 Jul; 87(7):743-5. PubMed ID: 22573520
    [Abstract] [Full Text] [Related]

  • 2. A phase 1 trial of eltrombopag in patients undergoing stem cell transplantation after total body irradiation.
    Liesveld JL, Phillips GL, Becker M, Constine LS, Friedberg J, Andolina JR, Milner LA, DeBolt J, Smudzin T, Hyrien O, Erickson-Miller CL, Johnson BM, Dawson KL, Chen Y.
    Biol Blood Marrow Transplant; 2013 Dec; 19(12):1745-52. PubMed ID: 24120380
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.
    Platzbecker U, Wong RS, Verma A, Abboud C, Araujo S, Chiou TJ, Feigert J, Yeh SP, Götze K, Gorin NC, Greenberg P, Kambhampati S, Kim YJ, Lee JH, Lyons R, Ruggeri M, Santini V, Cheng G, Jang JH, Chen CY, Johnson B, Bennett J, Mannino F, Kamel YM, Stone N, Dougherty S, Chan G, Giagounidis A.
    Lancet Haematol; 2015 Oct; 2(10):e417-26. PubMed ID: 26686043
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.
    Oliva EN, Alati C, Santini V, Poloni A, Molteni A, Niscola P, Salvi F, Sanpaolo G, Balleari E, Germing U, Fenaux P, Stamatoullas A, Palumbo GA, Salutari P, Impera S, Avanzini P, Cortelezzi A, Liberati AM, Carluccio P, Buccisano F, Voso MT, Mancini S, Kulasekararaj A, Morabito F, Bocchia M, Cufari P, Spiriti MA, Santacaterina I, D'Errigo MG, Bova I, Zini G, Latagliata R.
    Lancet Haematol; 2017 Mar; 4(3):e127-e136. PubMed ID: 28162984
    [Abstract] [Full Text] [Related]

  • 11. Eltrombopag: an update on the novel, non-peptide thrombopoietin receptor agonist for the treatment of immune thrombocytopenia.
    Kühne T, Imbach P.
    Ann Hematol; 2010 Jul; 89 Suppl 1():67-74. PubMed ID: 20405290
    [Abstract] [Full Text] [Related]

  • 12. Eltrombopag for treatment of thrombocytopenia-associated disorders.
    Merli P, Strocchio L, Vinti L, Palumbo G, Locatelli F.
    Expert Opin Pharmacother; 2015 Jul; 16(14):2243-56. PubMed ID: 26364898
    [Abstract] [Full Text] [Related]

  • 13. Eltrombopag in chronic idiopathic thrombocytopenic purpura and HCV-related thrombocytopenia.
    Panzer S.
    Drugs Today (Barc); 2009 Feb; 45(2):93-9. PubMed ID: 19343229
    [Abstract] [Full Text] [Related]

  • 14. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations.
    Aoki T, Harada Y, Matsubara E, Suzuki T, Oyama T, Kasai M, Uchida T, Ogura M.
    J Clin Pharm Ther; 2012 Dec; 37(6):729-32. PubMed ID: 22583038
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Successful treatment of post-allogeneic hematopoietic transplant immune thrombocytopenia with eltrombopag].
    Narita Y, Uchiyama T, Mizumoto C, Takeoka T, Tomo K, Tsuji M, Ohno T.
    Rinsho Ketsueki; 2018 Dec; 59(11):2418-2422. PubMed ID: 30531136
    [Abstract] [Full Text] [Related]

  • 18. Eltrombopag. Idiopathic thrombocytopenic purpura after treatment failure: romiplostim is a better option.
    Prescrire Int; 2010 Feb; 19(105):15. PubMed ID: 20455333
    [Abstract] [Full Text] [Related]

  • 19. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study.
    Cheng G, Saleh MN, Marcher C, Vasey S, Mayer B, Aivado M, Arning M, Stone NL, Bussel JB.
    Lancet; 2011 Jan 29; 377(9763):393-402. PubMed ID: 20739054
    [Abstract] [Full Text] [Related]

  • 20. Eltrombopag for treatment of thrombocytopenia after allogeneic hematopoietic cell transplantation in children: Single-centre experience.
    Yaman Y, Elli M, Şahin Ş, Özdilli K, Bilgen H, Bayram N, Nepesov S, Anak S.
    Pediatr Transplant; 2021 Aug 29; 25(5):e13962. PubMed ID: 33452850
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.